Mudritinib, an ERBB2 inhibitor, was reported to eliminate AML cell both in vivo and in vitro [78] VEGFR2 is a ‘hot’ target in AML, and relevant to chemotherapy-sensitivity, pro-survival effect and angiogenesis in bone marrow [79, 80]. The gene discussed is KDR; the disease is acute myeloid leukemia.